

HypO₂ Regen Therapeutics

Preclinical Platform of Disease-modifying Prodrugs
to Durably Reverse the Course of Chronic Inflammatory Diseases (CIDs)

Initial indications: Periodontitis, IBD

January 21, 2026

Pioneering Chronic Inflammatory Disease (CID) Treatment



HO2RT- Game-changing Preclinical Prodrug Platform

Preclinical platform of disease-modifying prodrugs to durably treat CIDs by leveraging your own body's natural tissue regenerative processes to durably restore tissue integrity.

- HO2RT- novel proprietary platform of Small Molecule Drug Conjugate (SMDC) prodrugs



- JUST 2 SQ inj. —————> **Durable clinical benefit** (2 CID rodent models)

- Potential regulatory upside: PRIME in Europe, Fast-Track in the US, NCE eligibility

**First indication: Periodontitis to access \$400B CID market*
and demonstrate proof of relevance for treatment of CIDs**


**Management estimates, calculations available in data room*

Why Periodontitis First? A low-hanging fruit



Under \$50M Overall Development Cost, \$30B Peak Revenues*

- Neglected disease: 1B people WW, linked to > 50 serious diseases, no effective treatment
- No periodontitis-specific drug treatment: SOC invasive, painful, ineffective, INEFFECTIVE
- Unique opportunity to generate licensing revenues in 2Y from pet periodontitis product



*Management estimates, calculations available in data room

Investments may be speculative, illiquid and there is risk of total loss.

Copyright © 2025- HypO2Regen Therapeutics, Inc. - do not reproduce without authorization

3-Fold Problem of Current CID Treatments



3-Pronged Solution: HO2RT Prodrug Platform

Current Standard of Care	No tissue regeneration <ul style="list-style-type: none">• <u>No existing drug stops fibrotic scarring</u>: 70% Crohn's Disease pts develop intestinal fibrosis• Implants and grafts have no biological function + invasive	High-toxicity Not durable <ul style="list-style-type: none">• Black box warning-most prescribed IBD drugs causing poor compliance, more frequent/severe relapses, disease progression• Periimplantitis, drug resistance, pain	Expensive Life-long yearly or repeat 6-figure treatment
HO2RT drugs	Tissue Regeneration <ul style="list-style-type: none">• <u>Scarless tissue restoration</u> of structure + function• <u>Disease-modifying</u>, quasi total reversion of tissue damage	Low Toxicity Durable Effect <ul style="list-style-type: none">• <u>Retains proven benefits of RSCTs</u> (Regenerative Stem Cell Ther.)• <u>Halts remission-relapse cycles</u> and disease progression	Affordable <ul style="list-style-type: none">• Lower treatment costs• High clinician adoption• Increased addressable patient population


Solution: Game-changing Therapy

Pioneering Stem Cell Therapy WITHOUT Cell Manipulations

Therapeutic Concept: tissue regeneration by DRUG-induced stem cell effect
Easy, convenient, durable treatment of CIDs

HO2RT drugs harness the body's own natural tissue healing processes

- Retains the proven benefits of Stem Cell Therapies (SCT), *but* **WITHOUT risky, costly cell manipulations**
- Simple, Easy administration: NO need for multiple patient visits to specialty cell therapy centers




HO2RT-101 Preclinical Efficacy in Periodontitis


Complete, Durable Periodontium Regeneration in rodents



Do these nice properties translate into real, durable therapeutic regeneration? YES!



Just 2 subQ
8 days apart




Severe periodontitis rodent model (“LIP”): 10-day ligature around molar causes severe microbiome dysbiosis and resulting destructive inflammation of bone + soft tissues of the periodontium, replicating severe human periodontitis

Significant regeneration alveolar bone + soft tissue, confirmed by histology. Restoration of periodontium structure, architecture, function (100% tooth reattachment), + pulp activation.

mimics natural regeneration process underlying healthy tissue integrity

TAM, SAM, SOM – Human Periodontitis

2033 Estimate US+EUR & 10Y CAGR




* Management estimates- calculations available in data room

Competitive Positioning- SOC

Game-changing Therapy for Humans and Pets

HO₂R_x



* Only in humans

Going To Market

Human & Companion Animal Periodontitis

HO₂R_x

HO2RT-101

Patient Visits/Yr



General Dentist
3800

Periodontist
1500

**> 160M
undertreated
US+Eur**

US Dentists

General Dentists
159,245

Periodontists
5,542



Medtech sales force

Clinical Dev. Partnering

HO2RT-103

Pet Periodontitis



- 200 Mil US+EUR
- >1 visit/year
- Up to \$2500 cost

US + EUR Veterinarians

Small animal vets
400,000



Existing sales force

Out-licensing by 2H2027

Pre-market licensing fees est. \$ 2-3M

FINDINGS FROM THE ECONOMIST IMPACT REPORT:
**NOW IS THE TIME TO
TAKE GUM DISEASE SERIOUSLY**

For the full report, [click here](#).

This report was produced in partnership with Crest® + Oral-B® and the American Academy of Periodontology (AAP).

\$154 billion
The estimated cost of untreated gum disease in the US. Economic impact can be divided into three main areas:

- Direct costs for periodontal disease—about \$1.4B
- Indirect costs for dental complications—about \$100.4B
- Indirect costs for productivity loss—about \$50.1B

The Economist INTELLIGENCE UNIT

Time to take gum disease seriously
The societal and economic impact of periodontitis

The Economist INTELLIGENCE UNIT

The socioeconomic impact of periodontitis

Investments may be speculative, illiquid and there is risk of total loss.

Copyright © 2025- HypO2Regen Therapeutics, Inc. - do not reproduce without authorization

Experienced Team with Synergistic Expertise

Driven by an innovative approach to changing patient lives



Co-founders



Dr. Isabelle Gorrillot
Co-founder & CEO
30Y Biotech growth, BDL



Prof. Phillip Messersmith
Co-founder & CTO
Chair, BioEngineering
UC Berkeley

Clinical Advisors



Thomas W Campi, DVM, MVPM
CEO, Modulant BioSci,
Former Head of BDL, Elanco



Jean-Marc Dersot, DDS, PhD
Periodontist Consultant



A Prime Investment Opportunity



- **Huge platform market opportunity** - growing >\$100B Chronic Inflammatory Disease (CID) market
- **Versatile Platform of SMDC prodrugs** mimicking natural tissue regeneration
- **Periodontitis: low-hanging fruit to enter** the competitive CID market **and demonstrate** therapeutic relevance to most CIDs for broad indication expansion potential (e.g., CVD, NAFLD, IBD)
- **Expected high adoption** expressed by clinical practitioners and patients, high unmet medical need
- **Therapeutic concept proven to translate into meaningful clinical benefit** in severe Periodontitis and IBD rodent models, as well as other disease-relevant inflammatory tissue injuries
- **Risk/cost-mitigating strategy** monetizing the preclinical studies required for the HO2RT-101 (human CID) IND/CTA filing through **HO2RT-103** (dog periodontitis) **out-licensing by 2028**: >50% total PC costs offset by licensing fees plus \$7B additional royalty revenue stream (2030-40).

Contact

Isabelle M Gorrillot, PhD - CEO, cofounder

isabelleg@ho2rx.com